AU2018353112B2 - Targeted gene integration of NK inhibitors genes for improved immune cells therapy - Google Patents

Targeted gene integration of NK inhibitors genes for improved immune cells therapy Download PDF

Info

Publication number
AU2018353112B2
AU2018353112B2 AU2018353112A AU2018353112A AU2018353112B2 AU 2018353112 B2 AU2018353112 B2 AU 2018353112B2 AU 2018353112 A AU2018353112 A AU 2018353112A AU 2018353112 A AU2018353112 A AU 2018353112A AU 2018353112 B2 AU2018353112 B2 AU 2018353112B2
Authority
AU
Australia
Prior art keywords
cells
fsc
cell
car
talen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018353112A
Other languages
English (en)
Other versions
AU2018353112A1 (en
Inventor
Brian BUSSER
Philippe Duchateau
Alexandre Juillerat
Laurent Poirot
Julien Valton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellectis SA
Original Assignee
Cellectis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2017/076798 external-priority patent/WO2018073391A1/en
Application filed by Cellectis SA filed Critical Cellectis SA
Publication of AU2018353112A1 publication Critical patent/AU2018353112A1/en
Application granted granted Critical
Publication of AU2018353112B2 publication Critical patent/AU2018353112B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/36—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2018353112A 2017-10-19 2018-03-09 Targeted gene integration of NK inhibitors genes for improved immune cells therapy Active AU2018353112B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/EP2017/076798 WO2018073391A1 (en) 2016-10-19 2017-10-19 Targeted gene insertion for improved immune cells therapy
AUPCT/EP2017/076798 2017-10-19
EP2018053343 2018-02-09
EPPCT/EP2018/053343 2018-02-09
PCT/EP2018/055957 WO2019076486A1 (en) 2017-10-19 2018-03-09 TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR ENHANCED IMMUNE CELL THERAPY

Publications (2)

Publication Number Publication Date
AU2018353112A1 AU2018353112A1 (en) 2020-04-23
AU2018353112B2 true AU2018353112B2 (en) 2024-11-14

Family

ID=66173541

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018353112A Active AU2018353112B2 (en) 2017-10-19 2018-03-09 Targeted gene integration of NK inhibitors genes for improved immune cells therapy
AU2018351689A Active AU2018351689B2 (en) 2017-10-19 2018-04-16 Targeted gene integration of CRS inhibitor genes for improved immune cells therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018351689A Active AU2018351689B2 (en) 2017-10-19 2018-04-16 Targeted gene integration of CRS inhibitor genes for improved immune cells therapy

Country Status (10)

Country Link
US (2) US12209125B2 (enExample)
EP (2) EP3684919A1 (enExample)
JP (2) JP7621795B2 (enExample)
KR (2) KR20250007705A (enExample)
CN (1) CN111511903B (enExample)
AU (2) AU2018353112B2 (enExample)
CA (1) CA3084476A1 (enExample)
IL (1) IL273828B2 (enExample)
MX (1) MX2020004444A (enExample)
WO (2) WO2019076486A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018189360A1 (en) * 2017-04-13 2018-10-18 Cellectis New sequence specific reagents targeting ccr5 in primary hematopoietic cells
WO2019025800A1 (en) * 2017-08-02 2019-02-07 Autolus Limited CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
WO2019076486A1 (en) 2017-10-19 2019-04-25 Cellectis TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR ENHANCED IMMUNE CELL THERAPY
JP2021525530A (ja) 2018-06-01 2021-09-27 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ キメラ抗原受容体細胞治療薬を用いたサイトカイン放出症候群の抑制
US12378572B2 (en) 2018-09-07 2025-08-05 Crispr Therapeutics Ag Universal donor cells
CN110055224B (zh) * 2019-04-03 2023-06-30 深圳市体内生物医药科技有限公司 一种基因修饰的免疫细胞及其制备方法和应用
JP2022531185A (ja) 2019-04-30 2022-07-06 クリスパー セラピューティクス アクチェンゲゼルシャフト 遺伝子改変ｔ細胞を標的化するｃｄ１９を使用するｂ細胞悪性病変の同種細胞療法
MX2021013223A (es) 2019-05-01 2022-02-17 Juno Therapeutics Inc Celulas que expresan un receptor quimerico de un locus cd247 modificado, polinucleotidos relacionados y metodos.
PH12021553254A1 (en) * 2019-06-27 2022-09-19 Crispr Therapeutics Ag Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
EP4025224A1 (en) 2019-09-05 2022-07-13 CRISPR Therapeutics AG Universal donor cells
JP7753197B2 (ja) * 2019-09-05 2025-10-14 クリスパー セラピューティクス アクチェンゲゼルシャフト ユニバーサルドナー細胞
EP4031654A4 (en) * 2019-09-20 2023-11-22 The University of North Carolina at Chapel Hill MODIFIED T CELLS AND METHOD FOR PRODUCING THEREOF
IL294388A (en) 2020-01-14 2022-08-01 Synthekine Inc Il2 orthologs and methods of use
AU2021288224A1 (en) * 2020-06-11 2023-01-05 Novartis Ag ZBTB32 inhibitors and uses thereof
WO2021263075A1 (en) * 2020-06-26 2021-12-30 St. Jude Children's Research Hospital, Inc. Methods of generating an activation inducible expression system in immune cells
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
WO2022020860A2 (en) * 2020-07-24 2022-01-27 Board Of Regents, The University Of Texas System Engineered t cells and tumor-infiltrating lymphocytes to increase tumor killing
WO2022112596A1 (en) 2020-11-30 2022-06-02 Cellectis Sa Use of aminoquinoline compounds for higher gene integration
WO2022143783A1 (en) * 2020-12-29 2022-07-07 Edigene Therapeutics (Beijing) Inc. Methods of identifying t-cell modulating genes
KR20230146007A (ko) 2020-12-31 2023-10-18 크리스퍼 테라퓨틱스 아게 범용 공여자 세포
KR20240007179A (ko) * 2021-04-30 2024-01-16 셀렉티스 에스.에이. 고형 종양 암 면역 요법을 위한 새로운 항-muc1 car 및 유전자 편집된 면역세포
MX2023015153A (es) * 2021-07-01 2024-04-16 Ningbo T Maximum Biopharmaceuticals Co Ltd Polipéptido de unión a antígeno que se dirige a b7h3 y aplicación del mismo.
WO2023016514A1 (zh) * 2021-08-12 2023-02-16 苏州克睿基因生物科技有限公司 经修饰的细胞、其制备方法及应用
WO2023212566A1 (en) * 2022-04-25 2023-11-02 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for preventing t cell exhaustion
CN115820697B (zh) * 2022-09-23 2024-07-30 中国海洋大学 一种免疫细胞及其制备方法和应用
AU2024259472A1 (en) * 2023-04-20 2025-11-13 Peter Maccallum Cancer Institute Compositions and methods for immunotherapy - ii
WO2024258835A1 (en) * 2023-06-16 2024-12-19 The Trustees Of Columbia University In The City Of New York Removal of endogenous tcr chains for enhanced tcr-based immunotherapies
TW202509218A (zh) * 2023-07-12 2025-03-01 亨利傑克森軍方醫學基金會 用於抑制自然殺手細胞之組合物及方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
WO1994024277A1 (en) 1993-04-13 1994-10-27 Sloan-Kettering Institute For Cancer Research Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
WO1997033988A1 (en) 1996-03-12 1997-09-18 Sloan-Kettering Institute For Cancer Research Double mutants of dihydrofolate reductase and methods of using same
EP1147209A2 (en) 1999-02-03 2001-10-24 The Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
HK1047770A1 (zh) 2000-02-24 2003-03-07 Xcyte Therapies, Inc. 细胞的同时刺激与浓缩
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
JP2006518372A (ja) 2003-01-28 2006-08-10 セレクティス 脊椎動物の体組織においてエクスビボかつイントトで相同的組換えを誘発するためのメガヌクレアーゼの使用およびその応用
EP1620537B1 (en) 2003-03-14 2012-10-24 Cellectis SA Large volume ex vivo electroporation method
CN106834320B (zh) 2009-12-10 2021-05-25 明尼苏达大学董事会 Tal效应子介导的dna修饰
US20120189621A1 (en) * 2011-01-21 2012-07-26 Yann Dean Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists
EP2699593B2 (en) * 2011-04-20 2020-11-04 University of Washington Through Its Center for Commercialization Beta-2 microglobulin-deficient cells
HUE064187T2 (hu) 2012-05-25 2024-02-28 Cellectis Eljárás immunterápiára alkalmas allogén és immunszupresszív-rezisztens T-sejt módosítására
US20150283233A1 (en) * 2012-06-15 2015-10-08 Gencia Corporation Compositions and Methods for Enhancing Immune Responses
EP3763810A3 (en) * 2012-10-10 2021-07-14 Sangamo Therapeutics, Inc. T cell modifying compounds and uses thereof
AU2014273490B2 (en) * 2013-05-29 2019-05-09 Cellectis Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
EP3693384B1 (en) 2014-03-11 2024-01-24 Cellectis Method for generating t-cells compatible for allogenic transplantation
CN107109368A (zh) * 2014-10-07 2017-08-29 塞勒克提斯公司 用于调节car诱导的免疫细胞活性的方法
BR112017018224A2 (pt) * 2015-03-11 2018-04-17 Cellectis métodos para manipulação de célula t alogênica para aumentar sua persistência e/ou implante em pacientes
WO2016164492A2 (en) * 2015-04-06 2016-10-13 Regeneron Pharmaceuticals, Inc. Humanized t cell mediated immune responses in non-human animals
AU2016261600B2 (en) 2015-05-08 2021-09-23 President And Fellows Of Harvard College Universal donor stem cells and related methods
IL257105B (en) * 2015-07-31 2022-09-01 Univ Minnesota Modified cells and methods of therapy
US11091780B2 (en) * 2015-09-18 2021-08-17 The Regents Of The University Of California Methods for autocatalytic genome editing and neutralizing autocatalytic genome editing and compositions thereof
CN115806940A (zh) 2015-11-04 2023-03-17 菲特治疗公司 多能细胞的基因组工程改造
EP4012415A3 (en) 2015-12-04 2022-12-07 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
TW201740958A (zh) * 2016-01-15 2017-12-01 依圖比克斯公司 用於t細胞免疫療法之方法及組合物
AU2017336094A1 (en) * 2016-09-29 2019-04-18 Immunitybio, Inc. HLA class I-deficient NK-92 cells with decreased immunogenicity
CN106636090B (zh) 2016-10-11 2019-08-09 上海优卡迪生物医药科技有限公司 人源白细胞介素6的siRNA、重组表达CAR-T载体及其构建方法和应用
CN108148863B (zh) * 2016-12-05 2019-12-17 上海优卡迪生物医药科技有限公司 一种封闭il6r的用于缓解crs的car-t转基因载体及其构建方法和应用
WO2019076486A1 (en) 2017-10-19 2019-04-25 Cellectis TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR ENHANCED IMMUNE CELL THERAPY

Also Published As

Publication number Publication date
WO2019076489A1 (en) 2019-04-25
EP3684919A1 (en) 2020-07-29
AU2018353112A1 (en) 2020-04-23
KR20250007705A (ko) 2025-01-14
CN111511903B (zh) 2024-10-11
US20200407694A1 (en) 2020-12-31
IL273828B2 (en) 2024-06-01
IL273828A (en) 2020-05-31
RU2020115282A (ru) 2021-11-19
WO2019076486A1 (en) 2019-04-25
MX2020004444A (es) 2020-07-22
JP2023055884A (ja) 2023-04-18
EP3673049A1 (en) 2020-07-01
IL273828B1 (en) 2024-02-01
US12221478B2 (en) 2025-02-11
US20200237823A1 (en) 2020-07-30
KR20200075851A (ko) 2020-06-26
WO2019076486A9 (en) 2020-05-28
AU2018351689A1 (en) 2020-04-30
CN111511903A (zh) 2020-08-07
US12209125B2 (en) 2025-01-28
RU2020115282A3 (enExample) 2021-11-19
JP2020537528A (ja) 2020-12-24
CA3084476A1 (en) 2019-04-25
JP7621795B2 (ja) 2025-01-27
AU2018351689B2 (en) 2025-01-23

Similar Documents

Publication Publication Date Title
AU2018353112B2 (en) Targeted gene integration of NK inhibitors genes for improved immune cells therapy
AU2017347637B2 (en) Targeted gene insertion for improved immune cells therapy
AU2019279084B2 (en) Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
AU2018338647B2 (en) Novel platforms for co-stimulation, novel car designs and other enhancements for adoptive cellular therapy
AU2018306307B2 (en) Enhanced chimeric antigen receptors and use thereof
AU2018207281B2 (en) Modulating expression of polypeptides via new gene switch expression systems
CN110770348B (zh) 嵌合抗原受体细胞的制备及其用途
AU2017244108B2 (en) Chimeric antigen receptors targeting cancer
KR102698738B1 (ko) B-세포 성숙화 항원을 표적화하는 키메라 항원 수용체 및 그의 용도
AU2017248259A1 (en) Chimeric antigen receptor T cell compositions
AU2020230334A1 (en) Compositions and methods for immunooncology
AU2018221730A1 (en) Donor repair templates multiplex genome editing
KR20210114969A (ko) 변형 세포의 확장 및 용도
AU2017230011A1 (en) Genome edited immune effector cells
KR102795055B1 (ko) Car-t 세포 및 자가면역 질환
KR20190130608A (ko) 면역종양학을 위한 조성물 및 방법
WO2018218194A1 (en) Cblb endonuclease variants, compositions, and methods of use
WO2020072059A1 (en) Cblb endonuclease variants, compositions, and methods of use
CN116970083B (zh) 结合Trop2的抗体或Trop2抗原结合片段以及抗Trop2CAR和应用
WO2023235882A2 (en) Immunotherapy targeting egfr antigens
KR20230143135A (ko) Cd19+, cd20+ 또는 cd22+ 종양 또는 b-세포 유래 자가-면역질환을 치료하기 위한 car t-세포
RU2797304C2 (ru) Целевая генная интеграция генов-ингибиторов nk для улучшенной иммунной клеточной терапии
HK40060048B (zh) 间皮素特异性t细胞受体及其在免疫治疗中的应用
HK40040375A (en) B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)